Objective: Health behaviors are defined as activities that affect either health status or disease risk. They can be divided into 2 categories: risky behaviors and health promoting behaviors. The growing body of evidence indicates that unhealthy behaviors often cluster in young individuals. Patterns of health-related behaviors are significantly different among countries and even among various regions of a certain country. Method: The present study was conducted to assess the youths’ patterns of health attitude, health-related behaviors, and their mental and physical wellbeing. In this cross-sectional study, 800 university undergraduate students were selected using multistage cluster sampling method. Standard questionnaires were filled by students. Results: About 13.3% of students smoked regularly and 14.3% reported at least one occasion of drinking, and heavy drinking was quite prevalent. Of the students, 95% reported regular physical activity and exercise. Eating habits were not healthy among the majority of students, as there was a high consumption of fast food and salt, and only 23.9% had normal body weight. Self-care behaviors were not prevalent among the students (3.2% breast self-exam and 8.5% testicular self-examination). Conclusion: Many factors may affect positive and negative heath behaviors, including knowledge, beliefs and attitudes, legal constrains, social context, and economic status. However, lower health literacy leads to more negative health behaviors.

Objectives Propentofylline is a xanthine phosphodiesterase inhibitor and adenosine reuptake blocker with neuroprotective effects linked to anti-inflammatory and antiexcitatory properties. This is a double-blind, placebo-controlled trial investigating the potential beneficial effects of propentofylline, as an adjunctive treatment with risperidone, on the severity and behavioral abnormalities of autism spectrum disorder (ASD). Methods A total of 48 children with ASD were randomly allocated into 2 groups of risperidone (initiating at 0.5 mg/d) plus propentofylline (initiating at 300 mg/d) and risperidone plus placebo. The Aberrant Behavior Checklist—Community (ABC-C) and Childhood Autism Rating Scale (CARS) were used for the evaluation of ASD severity and behavioral disruptions at baseline, week 4, and week 10. Primary outcome measure of the study was ABC-C irritability subscale score, whereas CARS score along with other 4 subscales of ABC-C (lethargy/social withdrawal, stereotypic behavior, hyperactivity/noncompliance, and inappropriate speech subscales) were considered as secondary outcome measures. Results Results from the general linear model repeated measures analysis demonstrated significant time-treatment interaction on irritability subscale (F 1.55 = 3.45; P = 0.048) and CARS (F 1.41 = 4.08; P = 0.034) scores. Compared with the placebo group, children receiving propentofylline showed greater improvements in the CARS score (P = 0.037) from baseline to the study endpoint. Our results found no significant time-treatment effect on other subscales of ABC-C. Two trial groups were comparable based on the frequency of adverse effects. Conclusions Our findings demonstrated that adjunctive treatment with propentofylline is effective in alleviating disease severity and improving irritability in ASD patients. However, larger studies with longer durations are required to confirm these results.